Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the U.S.A., 2000-2003

British Journal of Dermatology

Volumn 154, Issue 5, 2006, Pages 950-958

  Cowden, A L ^a   Katz, K A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Advertising; Food and Drug Administration; Government regulation; Prescription medicines

Indexed keywords

ADAPALENE; BETAMETHASONE VALERATE; CYCLOSPORIN A; FEXOFENADINE; LORATADINE; LUXIQ; MEQUINOL PLUS RETINOIC ACID; RETINOIC ACID; TACROLIMUS; TERBINAFINE; UNCLASSIFIED DRUG;

ARTICLE; CONFIDENCE INTERVAL; DERMATOLOGY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; E-MAIL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HAZARD ASSESSMENT; PHYSICIAN; POSTAL MAIL; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

ADVERTISING; CORRESPONDENCE; DERMATOLOGIC AGENTS; DRUG INDUSTRY; HUMANS; PRESCRIPTIONS, DRUG; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33645834787     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07168.x     Document Type: Article

References (79)

1. U.S. Government Accounting Office. Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising has Limitations. Washington, DC Government Accountability Office Oct. 2002. Report no. GAO-03-177
2. National Institute for Health Care Management Foundation. Prescription Drug Expenditures in 2001: Another Year of Escalating Costs. Washington, DC National Institute for Health Care Management Foundation May 2002.
3. Schmit J. Drugmakers likely to lob softer pitches. USA Today 16 Mar. 2005 ; Sect. B:3.
4. National Institute for Health Care Management Foundation. Prescription Drugs and Mass Media Advertising, 2000. Washington, DC National Institute for Health Care Management Foundation Nov. 2001.
5. U.S. Food and Drug Administration. Prescription Drug Advertisements. 21 C.F.R. Sect. 202.1, 2004.
6. Slater EE. Today's FDA. N Engl J Med 2005 352 293 7.
7. Elliott S. The F.D.A. may ask drug advertisers to make information on side effects more prominent. New York Times 5 Feb. 2004 ; Sect. C:15 (col. 1).
8. Bhattacharyya T Tornetta P 3rd. Healy WL Einhorn TA. The validity of claims made in orthopaedic print advertisements. J Bone Joint Surg Am 2003 85A 1224 8.
9. Mindell J Kemp T. Evidence based advertising? Only two fifths of advertisements cited published, peer reviewed references. BMJ 1997 315 1622.
10. Smart S Williams C. Evidence based advertising? Half of drug advertisements in BMJ over six months cited no supporting evidence. BMJ 1997 315 1622 3.
11. Cooper RJ Schriger DL Wallace RC et al. The quantity and quality of scientific graphs in pharmaceutical advertisements. J Gen Intern Med 2003 18 294 7.
12. Gutknecht DR. Evidence-based advertising? A survey of four major journals. J Am Board Fam Pract 2001 14 197 200.
13. Herxheimer A Lundborg CS Westerholm B. Advertisements for medicines in leading medical journals in 18 countries: a 12-month survey of information content and standards. Int J Health Serv 1993 23 161 72.
14. Hopcroft D. References in medical advertising - too often a blend of fact and fiction? NZ Med J 2002 115 294 5.
15. Loke TW Koh FC Ward JE. Pharmaceutical advertisement claims in Australian medical publications. Med J Aust 2002 177 291 3.
16. Wilkes MS Doblin BH Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med 1992 116 912 19.
17. Villanueva P Peiro S Librero J Pereiro I. Accuracy of pharmaceutical advertisements in medical journals. Lancet 2003 361 27 32.
18. Vlassov V Mansfield P Lexchin J Vlassova A. Do drug advertisements in Russian medical journals provide essential information for safe prescribing? West J Med 2001 174 391 4.
19. Lankinen KS Levola T Marttinen K et al. Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals. Pharmacoepidemiol Drug Saf 2004 13 789 95.
20. Chao BA. Evaluating the educational content of direct-to-consumer fulfillment materials. Am J Health Syst Pharm 2005 62 620 5.
21. Hogan DJ Sarel D Canas A et al. An analysis of advertisements in the Journal of the American Academy of Dermatology, 1980 and 1990. J Am Acad Dermatol 1993 28 993 7.
22. Angel JE. An analysis of advertisements. J Am Acad Dermatol 1994 31 136 8.
23. Marketing drugs to unsuitable patients. New York Times 28 Jan. 2005 ; Sect. A:22 (col. 1).
24. Reining in direct-to-consumer advertising. Lancet 2005 365 1204.
25. Hollon MF. Direct-to-consumer advertising: a haphazard approach to health promotion. JAMA 2005 293 2030 3.
26. Bowe C. Bristol-Myers adopts advertising code. Financial Times (USA edn 2) 15 June 2005 22.
27. Henderson D. FDA to get tougher on ads. Boston Globe 25 Feb. 2005 Sect. E:1.
28. Harris G. Federal Drug Agency calls ads for the cholesterol pill Crestor 'False and Misleading.' New York Times 22 Dec. 2004 Sect. A:16 (col. 1).
29. Elliot S Ives N. Selling prescription drugs to the consumer. New York Times 12 Oct. 2004 Sect. C:1 (col. 2).
30. Steinberg B. Novartis brings back 'Digger' to TV spots for Lamisil drug. Wall Street Journal 22 Mar. 2004 Sect. B:7 (col. 5).
31. Misleading drug ads slip under regulators' radar. USA Today 6 Jan. 2003 Sect. A:12.
32. Schmit J. A winded FDA races to keep up with drug ads that go too far. USA Today 31 May 2005 Sect. A:1.
33. Restricting drug ads not a good prescription. USA Today 13 June 2005 Sect. A:12.
34. Querna B. The big pill pitch. Newsweek 6 June 2005 52 3.
35. Saul S. A.M.A. to study effect of marketing drugs to consumers. New York Times 22 June 2005 Sect. C:7 (col. 2).
36. Lenzer J. American Medical Association rejects proposal to ban consumer adverts for prescription medicines. BMJ 2005 331 7.
37. US House of Representatives Committee on Government Reform - Minority Staff Special Investigations. FDA Enforcement Actions against False and Misleading Prescription Drug Advertisements Declined in 2003. Washington, DC United States House of Representatives Committee on Government Reform - Minority Staff Special Investigations Division Jan. 2004.
38. Schmit J. Voluntary guidelines vs. legislation. USA Today 31 May 2005 Sect. A:4.
39. Kusserow RP. Prescription Drug Advertisements in Medical Journals. Washington, DC Department of Health and Human Services, Office of Inspector General June 2002.
40. Mathews AW. Consumer ads draw FDA scrutiny. Wall Street Journal 21 Aug. 2003 Sect. D:3.
41. Rowland C. FDA vows tough treatment for drug ads. Boston Globe 4 Mar. 2005 Sect. C:1.
42. Food and Drug Administration [homepage on the internet]. Transfer of Therapeutic Products to the Center for Drug Evaluation and Research. Washington, DC FDA [updated 27 Sep. 2004; cited 3 Jan. 2005 [about 2 screens] ( http://www.fda.gov/cber/transfer/transfer.htm ).
43. Scheman A Severson D. Pocket Guide to Medications Used in Dermatology. Philadelphia Lippincott Williams and Wilkins 2003.
44. Altman DG. Practical Statistics for Medical Research 1st edn. London Chapman and Hall 1991.
45. Food and Drug Administration Safety Act of 2005, S. 930. 109th Cong., 1st Sess. 2005
46. Bowe C. Senate leader steps up the pressure on drug adverts. Financial Times (USA edn 2) 2 July 2005 9.
47. Mansfield PR Mintzes B Richards D Toop L. Direct to consumer advertising. BMJ 2005 330 5 6.
48. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Bill, 2006, House Report 109-102, 2 June 2005.
49. The Henry J. Kaiser Family Foundation. Kaiser Health Poll Report; January/February 2005 Featured Topic: Views on Prescription Drugs and the Pharmaceutical Industry. Menlo Park, CA 2005 ( http://www.kff.org/ healthpollreport/feb_2005/index.cfm ).
50. Spiller LD Wymer WW Jr.. Physicians' perceptions and uses of commercial drug information sources: an examination of pharmaceutical marketing to physicians. Health Mark Q 2001 19 91 106.
51. Avorn J Chen M Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982 73 4 8.
52. Aikin KJ Swasy JL Braman AC. Patient and Physician Attitudes and Behaviors Associated With DTC Promotion of Prescription Drugs - Summary of FDA Survey Research Results. Washington, DC U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Nov. 2004.
53. IMS Health [homepage on the internet]. IMS Study: U.S. Physicians Responsive to Patient Requests for Brand-Name Drugs. Fairfield, CT IMS Health c2004 [cited 30 Dec. 2004] [about 1 screen] ( http://www.imshealth.com/ims/ portal/front/articleC/0,2777,6599_3665_1003811,00.html ).
54. Bell RA Kravitz RL Wilkes MS. Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med 1999 14 651 7.
55. Berndt ER. To inform or persuade? Direct-to-consumer advertising of prescription drugs. N Engl J Med 2005 352 325 8.
56. Kravitz RL Epstein RM Feldman MD et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005 293 1995 2002.
57. Pharmaceutical Research and Manufacturers of America. PhRMA Guiding Principles: Direct to Consumer Advertisements About Prescription Medicines. Washington, DC PhRMA Aug 2005 [cited 8 Aug. 2005] ( http://www.phrma.org ).
58. Saul S. Drug makers to police consumer campaigns. New York Times 3 Aug. 2005 Sect. C:7 (col. 1).
59. Oliver JJ Maxwell SR. Journals should select drug advertisements more carefully. BMJ 2003 326 1211.
60. Wilkes MS Kravitz RL. Policies, practices, and attitudes of North American medical journal editors. J Gen Intern Med 1995 10 443 50.
61. Bartus CL Katz KA. Advertising in dermatology journals: journals' and journal editors' policies, practices, and attitudes. J Am Acad Dermatol in press
62. Fletcher RH. Adverts in medical journals: caveat lector. Lancet 2003 361 10 11.
63. Kessler DA. Addressing the problem of misleading advertising. Ann Intern Med 1992 116 950 1.
64. Rennie D. Editors and advertisements. What responsibility do editors have for the advertisements in their journals? JAMA 1991 265 2394 6.
65. Goyan JE. Who reviews the ads? N Engl J Med 1980 302 296.
66. Tansey B. Citizens use law to pursue drug firms; citing unfair competition and weak FDA oversight, consumer coalition sues giant pharmaceutical companies. San Francisco Chronicle 23 Nov. 2003 Sect. I:1.
67. Prescription Access Litigation [homepage on the internet]. Neurontin Off-Label Promotions Case ('Neurontin II'). Boston Community Catalyst, Inc. c2004 [cited 2 Jan. 2005] [about 2 screens] ( http://www. prescriptionaccesslitigation.org/neurontin_ii.htm ).
68. Prescription Access Litigation [homepage on the internet]. Nexium. Boston Community Catalyst, Inc. c2004 [cited 2 Jan. 2005] [about 2 screens] ( http://www.prescriptionaccesslitigation.org/nexium.htm ).
69. McCoy K. Texas files suit against Merck over Vioxx. USA Today 1 July 2005 Sect. B:6.
70. Europe on the brink of direct-to-consumer drug advertising. Lancet 2002 359 1709.
71. Medicines and Healthcare products Regulatory Agency [homepage on the internet]. London MHRA c2005 [updated 11 Aug. 2005; cited 14 Aug. 2005] ( http://www.mhra.gov.uk/ ).
72. Medicines and Healthcare products Regulatory Agency [homepage on the internet]. Regulation of the Promotion of Medicines: Investigation of Complaints about Advertising. London MHRA 2005 [updated 11 Aug. 2005; cited 14 Aug. 2005] [about 6 screens] ( http://medicines.mhra.gov.uk/ourwork/advertpromed/ complaints/complaints.htm ).
73. The Association of the British Pharmaceutical Industry [homepage on the internet]. Prescription Medicines Code of Practice Authority. London ABPI 2005 [cited 14 Aug. 2005] [about 2 screens] ( http://www.abpi.org.uk/links/assoc/ pmcpa.asp ).
74. Prescription Medicines Code of Practice Autority. Annual Report for 2003. London Prescription Medicines Code of Practice Authority 2003 [cited 14 Aug. 2005] ( http://www.abpi.org.uk/links/assoc/PMCPA/Annual%20report%202003.pdf ).
75. Prescription Medicines Code of Practice Autority. Code of Practice Review. London Prescription Medicines Code of Practice Authority 2003 [cited 14 Aug. 2005] ( http://ww.abpi.org.uk ).
76. U.S. Food and Drug Administration. FDA's Electronic Freedom of Information Reading Room-Warning Letters and Responses [database on the internet]. Washington, DC Food and Drug Administration [cited 1 Jan. 2005 ] ( http://www.fda.gov/foi/warning.htm ).
77. U.S. Food and Drug Administration. Allergan, Inc. Warning Letter. FDA's Electronic Freedom of Information Reading Room - Warning Letters and Responses [database on the internet], 23 June 2003 [cited 1 Jan. 2005] [about 2 screens] ( http://www.fda.gov/foi/warning_letters/g4093d.htm ).
78. Kaufman M Masters BA. FDA is flexing less muscle; some question its relationship with drugmakers. Washington Post 18 Nov. 2004 Sect. A:1.
79. Federal Trade Commission [homepage on the internet]. Guide to the Federal Trade Commission.